A single centre, cohort, retrospective study predicting development of ipilimumab-induced hypophysitis in patients treated for advanced melanoma
Latest Information Update: 28 May 2020
At a glance
- Drugs Ipilimumab (Primary) ; Ipilimumab/nivolumab
- Indications Malignant melanoma
- Focus Adverse reactions
- 28 May 2020 New trial record
- 24 May 2020 Results published in the Journal of Endocrinological Investigation